drugset / Trial / NCT00661895

Black Education and Treatment of Hypertension (BEAT HTN)

NCT00661895

Phase 4 Completed 99 enrolled Creighton University
RandomizedParallel-groupOpen-labelTreatment

Summary

Clinical trials have yet to test the adequacy of HTN control in African Americans (AA) when both control and intervention groups are given free antihypertensive medications and are involved in usual versus intensive intervention strategies. Because of this, it has not yet been determined whether the method of prescribing antihypertensive medications according to JNC 7 guidelines is more, less, or equally as effective as prescribing antihypertensive medications and providing intensive behavioral and clinical interventions. Knowledge in this area of HTN treatment should better able medical and health practitioners to help their AA subjects control HTN. The BEAT Hypertension Clinic will evaluate this method of HTN control by proposing a program that will evaluate the difference in HTN control among subjects receiving usual care and free medications and subjects also receiving free medications, but additionally being treated in a clinic that operates in a more intensive manner in relationship to patient behavior modification, patient-clinician interactions, and physical and social environments. At the conclusion of the study, the BEAT Hypertension Clinic investigators will report findings and help to answer the question of whether medication alone or medication combined with intensive behavioral and clinical treatment is more effective in HTN control in the AA population.

Timeline

Start
2005-08
Primary completion
2009-08
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Background Amlodipine Other / unclassified 5 mg
Background Amlodipine Other / unclassified 10 mg
Background Atenolol Other / unclassified 50 mg
Background Clonidine Other / unclassified 0.2 mg
Background Doxazosin Small molecule 4 mg
Background Hydralazine Small molecule 50 mg
Background Hydrochlorothiazide Unknown 12.5 mg
Background Hydrochlorothiazide Unknown 25 mg
Background LISINOPRIL ANHYDROUS Small molecule 5 mg
Background LISINOPRIL ANHYDROUS Small molecule 10 mg
Background LISINOPRIL ANHYDROUS Small molecule 20 mg
Background Metoprolol Other / unclassified 50 mg
Background Metoprolol Other / unclassified 100 mg
Background Nifedipine XL Unknown 30 mg
Background Nifedipine XL Unknown 60 mg
Background Valsartan Small molecule 80 mg
Background Valsartan Small molecule 160 mg

Indications